5.2% of combined E.coli, K.pneumoniae, and P.mirabilis isolates were ESBL (extended spectrum beta-lactamase) positive
5.2% of combined E.coli, K.pneumoniae, and P.mirabilis isolates were ESBL (extended spectrum beta-lactamase) positive
5.2% of combined E.coli, K.pneumoniae, and P.mirabilis isolates were ESBL (extended spectrum beta-lactamase) positive
May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.
May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.
May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.
May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.
May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.
